Nothing Special   »   [go: up one dir, main page]

RU2001126396A - SET FOR RADIOACTIVE LABELING OF PROTEINS ITTREM-90 - Google Patents

SET FOR RADIOACTIVE LABELING OF PROTEINS ITTREM-90

Info

Publication number
RU2001126396A
RU2001126396A RU2001126396/04A RU2001126396A RU2001126396A RU 2001126396 A RU2001126396 A RU 2001126396A RU 2001126396/04 A RU2001126396/04 A RU 2001126396/04A RU 2001126396 A RU2001126396 A RU 2001126396A RU 2001126396 A RU2001126396 A RU 2001126396A
Authority
RU
Russia
Prior art keywords
kit
buffer
chelator
dtpa
radioisotope
Prior art date
Application number
RU2001126396/04A
Other languages
Russian (ru)
Other versions
RU2221807C2 (en
Inventor
Пол ЧИНН
Original Assignee
Айдек Фармасьютикалз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айдек Фармасьютикалз Корпорейшн filed Critical Айдек Фармасьютикалз Корпорейшн
Publication of RU2001126396A publication Critical patent/RU2001126396A/en
Application granted granted Critical
Publication of RU2221807C2 publication Critical patent/RU2221807C2/en

Links

Claims (48)

1. Способ радиоактивного мечения конъюгированного с хелатором белка или пептида терапевтическим радиоактивным изотопом для введения пациенту, заключающийся в том, что смешивают конъюгированный с хелатором белок или пептид с раствором, содержащим радиоактивный изотоп или его соль, и инкубируют эту смесь в течение достаточного количества времени при подходящих условиях, при этом образуется радиоактивно меченый белок или пептид, имеющий достаточные чистоту, удельную активность и специфичность связывания, так что полученное радиоактивно меченое антитело может вводиться непосредственно пациенту без дополнительной очистки.1. A method for radiolabelling a chelator-conjugated protein or peptide with a therapeutic radioactive isotope for administration to a patient, the method is that the chelator-conjugated protein or peptide is mixed with a solution containing the radioactive isotope or its salt, and the mixture is incubated for a sufficient amount of time at under suitable conditions, a radioactively labeled protein or peptide is formed having sufficient purity, specific activity and binding specificity, so that the resulting radioactively labeled antibody can be administered directly to the patient without further purification. 2. Способ по п.1, в котором указанный терапевтический радиоизотоп выбирают из группы, состоящей из альфа- и бета-излучателей.2. The method according to claim 1, wherein said therapeutic radioisotope is selected from the group consisting of alpha and beta emitters. 3. Способ по п.2, в котором в качестве указанного радиоизотопа используют бета-излучатель.3. The method according to claim 2, in which a beta emitter is used as the specified radioisotope. 4. Способ по п.3, в котором указанный бета-излучатель представляет собой 90Y.4. The method according to claim 3, wherein said beta emitter is 90 Y. 5. Способ по п.1, в котором указанный белок является антителом или фрагментом антитела.5. The method according to claim 1, wherein said protein is an antibody or antibody fragment. 6. Способ по п.4, в котором указанное достаточное время инкубации составляет менее восьми минут.6. The method according to claim 4, in which the indicated sufficient incubation time is less than eight minutes. 7. Способ по п.6, в котором указанное достаточное время инкубации находится в пределах от около двух до около пяти минут.7. The method according to claim 6, in which the specified sufficient incubation time is in the range from about two to about five minutes. 8. Способ по п.1, в котором используют хелатор, являющийся бифункциональным хелатором, выбранным из группы, состоящей из MX-DTPA, фенил-DTPA, бензил-DTPA, CHX-DTPA, DOTA и их производных.8. The method according to claim 1, wherein a chelator is used, which is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and their derivatives. 9. Способ по п.8, в котором указанный хелатор представляет собой MX-DTPA.9. The method of claim 8, wherein said chelator is MX-DTPA. 10. Способ по п.4, в котором в качестве подходящих условий рассматривают приемлемые условия температуры, рН и буфера.10. The method according to claim 4, in which suitable conditions are considered acceptable conditions of temperature, pH and buffer. 11. Способ по п.10, в котором указанная приемлемая температура находится в диапазоне от около 25 до около 43°С.11. The method according to claim 10, in which the specified acceptable temperature is in the range from about 25 to about 43 ° C. 12. Способ по п.10, в котором указанная приемлемая величина рН находится в диапазоне от около 3,0 до около 6,0.12. The method according to claim 10, in which the specified acceptable pH is in the range from about 3.0 to about 6.0. 13. Способ по п.10, в котором указанный приемлемый буфер является ацетатным буфером.13. The method of claim 10, wherein said acceptable buffer is an acetate buffer. 14. Способ по п.13, в котором указанный буфер является ацетатом натрия и присутствует в концентрации от около 10 до около 1000 мМ.14. The method according to item 13, in which the specified buffer is sodium acetate and is present in a concentration of from about 10 to about 1000 mm. 15. Способ по п.10, в котором указанный приемлемый буфер содержит мягкий радиопротектор.15. The method of claim 10, wherein said acceptable buffer comprises a soft radioprotector. 16. Способ по п.15, в котором в качестве мягкого радиопротектора используют аскорбат.16. The method according to clause 15, in which ascorbate is used as a soft radioprotector. 17. Способ по п.1, в котором достигают уровень включения радиоизотопа по меньшей мере приблизительно 95%.17. The method according to claim 1, wherein the radioisotope incorporation level of at least about 95% is achieved. 18. Способ по п.1, в котором специфичность связывания равна по меньшей мере 70%.18. The method according to claim 1, in which the specificity of the binding is at least 70%. 19. Способ по п.5, в котором используют антитело, являющееся меченым до удельной активности по меньшей мере 5 мКи/мг.19. The method according to claim 5, in which an antibody is used that is labeled to a specific activity of at least 5 mCi / mg. 20. Набор для радиоактивного мечения конъюгированного с хелатором белка или пептида терапевтическим радиоактивным изотопом для введения пациенту, содержащий флакон, содержащий конъюгированный с хелатором белок или пептид в подходящем буфере, флакон, содержащий буфер композиции для стабилизации и введения радиоактивно меченого антитела пациенту, и инструкции для проведения процедуры радиоактивного мечения, при которой конъюгированный с хелатором белок или пептид экспонируется радиоизотопу или его соли в течение достаточного количества времени при подходящих условиях, рекомендуемых в указанных инструкциях, с получением радиоактивно меченого белка или пептида, имеющего достаточные чистоту, удельную активность и специфичность связывания, так что полученное радиоактивно меченое антитело подвергается разведению до подходящей концентрации в указанном буфере композиции и введению непосредственно пациенту без дополнительной очистки.20. A kit for radiolabeling a chelator-conjugated protein or peptide with a therapeutic radioactive isotope for administration to a patient, comprising a vial containing a chelator-conjugated protein or peptide in a suitable buffer, a vial containing a composition buffer for stabilizing and administering a radiolabeled antibody to a patient, and instructions for a radiolabeling procedure in which a chelator-conjugated protein or peptide is exposed to a radioisotope or its salt for a sufficient amount at appropriate conditions recommended in these instructions, to obtain a radiolabeled protein or peptide having sufficient purity, specific activity and binding specificity, so that the resulting radiolabeled antibody is diluted to a suitable concentration in the indicated buffer of the composition and administered directly to the patient without additional cleaning up. 21. Набор по п.20, в котором указанный терапевтический радиоизотоп является альфа- или бета-излучающим радиоизотопом.21. The kit of claim 20, wherein said therapeutic radioisotope is an alpha or beta emitting radioisotope. 22. Набор по п.21, в котором указанный терапевтический радиоизотоп является бета-излучателем.22. The kit of claim 21, wherein said therapeutic radioisotope is a beta emitter. 23. Набор по п.22, в котором указанный бета-излучатель является 90Y.23. The kit of claim 22, wherein said beta emitter is 90 Y. 24. Набор по п.20, в котором указанный белок является антителом или фрагментом антитела.24. The kit of claim 20, wherein said protein is an antibody or antibody fragment. 25. Набор по п.23, в котором указанное достаточное время инкубации составляет менее восьми минут.25. The kit of claim 23, wherein said sufficient incubation time is less than eight minutes. 26. Набор по п.25, в котором указанное достаточное время инкубации находится в пределах от около двух до около пяти минут.26. The kit of claim 25, wherein said sufficient incubation time is in the range of about two to about five minutes. 27. Набор по п.20, в котором указанный хелатор является бифункциональным хелатором, выбранным из группы, состоящей из MX-DTPA, фенил-DTPA, бензил-DTPA, CHX-DTPA, DOTA и их производных.27. The kit of claim 20, wherein said chelator is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and derivatives thereof. 28. Набор по п.27, в котором указанный хелатор представляет собой MX-DTPA.28. The kit of claim 27, wherein said chelator is MX-DTPA. 29. Набор по п.20, в котором указанные подходящие условия обозначают приемлемые условия температуры, рН и буфера.29. The kit of claim 20, wherein said suitable conditions indicate acceptable conditions of temperature, pH, and buffer. 30. Набор по п.29, в котором указанная приемлемая температура находится в диапазоне от около 25 до около 43°С.30. The kit according to clause 29, in which the specified acceptable temperature is in the range from about 25 to about 43 ° C. 31. Набор по п.29, в котором указанная приемлемая величина рН находится в диапазоне от приблизительно 3,0 до приблизительно 6,0.31. The kit according to clause 29, in which the specified acceptable pH is in the range from about 3.0 to about 6.0. 32. Набор по п.29, в котором указанный приемлемый буфер является ацетатным буфером.32. The kit according to clause 29, wherein said acceptable buffer is an acetate buffer. 33. Набор по п.32, в котором указанный буфер является ацетатом натрия и присутствует в концентрации от около 10 до около 1000 мМ.33. The kit of claim 32, wherein said buffer is sodium acetate and is present in a concentration of from about 10 to about 1000 mM. 34. Набор по п.29, в котором указанный приемлемый буфер содержит мягкий радиопротектор.34. The kit according to clause 29, in which the specified acceptable buffer contains a soft radioprotector. 35. Набор по п.34, в котором мягким радиопротектором является аскорбат.35. The kit according to clause 34, in which the soft radioprotector is ascorbate. 36. Набор по п.20, в котором достигается уровень включения радиоизотопа по меньшей мере приблизительно 95%.36. The kit of claim 20, wherein the radioisotope incorporation level of at least about 95% is achieved. 37. Набор по п.20, в котором специфичность связывания равна по меньшей мере 70%.37. The kit of claim 20, wherein the binding specificity is at least 70%. 38. Набор по п.23, в котором антитело является меченым до удельной активности по меньшей мере 5 мКи/мг.38. The kit of claim 23, wherein the antibody is labeled to a specific activity of at least 5 mCi / mg. 39. Набор по п.20, который дополнительно содержит флакон стерильного буфера для коррекции рН радиоизотопа.39. The kit according to claim 20, which further comprises a bottle of sterile buffer for adjusting the pH of the radioisotope. 40. Набор по п.39, в котором указанный флакон содержит ацетатный буфер.40. The kit of claim 39, wherein said vial contains acetate buffer. 41. Набор по п.20, в котором указанный буфер композиции содержит физиологический солевой раствор, радиопротектор и неконъюгированный хелатор.41. The kit of claim 20, wherein said composition buffer comprises physiological saline, a radioprotector, and an unconjugated chelator. 42. Набор по п.41, в котором радиопротектор выбран из группы, состоящей из человеческого сывороточного альбумина (HSA), аскорбата, аскорбиновой кислоты, фенола, сульфитов, глутатиона, цистеина, гентизиновой кислоты, никотиновой кислоты, аскорбилпальмитата, НОР(:О)Н2, глицерина, сульфоксилата формальдегида натрия, Na2S2O5, Na2S2О3 и SO2.42. The kit according to paragraph 41, wherein the radioprotector is selected from the group consisting of human serum albumin (HSA), ascorbate, ascorbic acid, phenol, sulfites, glutathione, cysteine, gentisic acid, nicotinic acid, ascorbyl palmitate, HOP (: O) H 2 , glycerol, sodium formaldehyde sulfoxylate, Na 2 S 2 O 5 , Na 2 S 2 O 3 and SO 2 . 43. Набор по п.42, в котором радиопротектор является аскорбатом.43. The kit of claim 42, wherein the radioprotector is an ascorbate. 44. Набор по п.43, в котором концентрация аскорбата составляет приблизительно 1-100 мг/мл.44. The kit according to item 43, in which the concentration of ascorbate is approximately 1-100 mg / ml 45. Набор по п.42, в котором неконъюгированным хелатором является DTPA.45. The kit of claim 42, wherein the unconjugated chelator is DTPA. 46. Набор по п.45, в котором концентрация DTPA равна приблизительно 1 мМ.46. The kit according to item 45, in which the concentration of DTPA is approximately 1 mm. 47. Набор по п.20, который дополнительно содержит реакционный флакон.47. The kit according to claim 20, which further comprises a reaction vial. 48. Набор по п.20, который дополнительно содержит флакон радиоизотопа.48. The kit according to claim 20, which further comprises a bottle of a radioisotope.
RU2001126396/04A 1999-03-01 2000-02-29 Method for radioactive labeling proteins with therapeutic radioactive isotope and set for method realization RU2221807C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25933899A 1999-03-01 1999-03-01
US09/259,338 1999-03-01

Publications (2)

Publication Number Publication Date
RU2001126396A true RU2001126396A (en) 2003-06-27
RU2221807C2 RU2221807C2 (en) 2004-01-20

Family

ID=22984528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001126396/04A RU2221807C2 (en) 1999-03-01 2000-02-29 Method for radioactive labeling proteins with therapeutic radioactive isotope and set for method realization

Country Status (36)

Country Link
US (3) US6994840B1 (en)
EP (2) EP1156835B1 (en)
JP (1) JP4558947B2 (en)
KR (1) KR100734023B1 (en)
CN (1) CN1251767C (en)
AT (1) ATE428446T1 (en)
AU (1) AU780311B2 (en)
BG (1) BG65568B1 (en)
BR (1) BR0008635A (en)
CA (1) CA2362908C (en)
CY (1) CY1109211T1 (en)
CZ (1) CZ20013127A3 (en)
DE (2) DE1156835T1 (en)
DK (1) DK1156835T3 (en)
EE (1) EE05582B1 (en)
ES (1) ES2165830T3 (en)
GR (1) GR20010300078T1 (en)
HK (1) HK1045656B (en)
HR (1) HRP20010713A2 (en)
HU (1) HU227986B1 (en)
IL (2) IL145112A0 (en)
ME (1) ME00783B (en)
MX (1) MXPA01008745A (en)
MY (1) MY133346A (en)
NO (1) NO330728B1 (en)
NZ (1) NZ513667A (en)
PL (1) PL204239B1 (en)
PT (1) PT1156835E (en)
RS (1) RS50342B (en)
RU (1) RU2221807C2 (en)
SI (1) SI1156835T1 (en)
SK (1) SK287650B6 (en)
TW (1) TWI283178B (en)
UA (1) UA75036C2 (en)
WO (1) WO2000052031A2 (en)
ZA (1) ZA200106945B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2001296545A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Methods of therapy for b-cell malignancies
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US6974563B2 (en) 2002-06-18 2005-12-13 Lynntech, Inc. Ion exchange materials for the separation of 90Y from 90SR
EA200501197A1 (en) * 2003-01-27 2006-04-28 Байоджен Айдек Ма Инк. COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALIGNANT TUMOR USING IGSF9 AND LIV - 1
EA008195B1 (en) * 2003-04-15 2007-04-27 Алгета Ас Thorium-227 for use in radiotherapy of soft tissue disease
CN1929862B (en) 2003-11-04 2012-02-15 诺华疫苗和诊断公司 Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
JP4765038B2 (en) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Method for treating solid tumors expressing CD40 cell surface antigen
PL1684805T3 (en) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
DK1684869T3 (en) 2003-11-04 2011-10-31 Novartis Vaccines & Diagnostic Method of Therapy for B-Cell-Related Cancer Diseases
CA2544853C (en) 2003-11-04 2014-05-20 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases, and organ transplant rejection
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102143974B (en) 2008-07-16 2015-03-25 生命医学研究学会 Human cytomegalovirus neutralising antibodies and use thereof
PE20141432A1 (en) 2008-07-16 2014-10-18 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
CN102216327A (en) 2008-07-25 2011-10-12 生物医学研究所 Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2739551C (en) 2008-10-13 2019-03-05 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
MX2013007371A (en) * 2010-12-22 2014-05-27 Affibody Ab Radiolabled her2 binding peptides.
CN103717617B (en) 2011-07-18 2017-06-20 生物医学学会 Neutralize anti-influenza A virus antibody and application thereof
AU2013237087B2 (en) 2012-03-20 2017-07-20 Humabs Biomed Sa Antibodies that neutralize RSV, MPV and PVM and uses thereof
RU2537175C2 (en) * 2013-03-26 2014-12-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Method for producing radioimmune preparation for diagnosing and treating oncological diseases
CR20190319A (en) 2013-08-13 2019-08-29 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
DK3052192T3 (en) 2013-10-02 2020-09-28 Medimmune Llc NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR112017010298B1 (en) 2014-11-18 2023-10-31 Humabs Biomed Sa ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSAVIRUS, USES THEREOF, NUCLEIC ACID MOLECULE, VECTOR, ISOLATED CELL, PHARMACEUTICAL COMPOSITION, AND KIT OF PARTS
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
JP6867306B2 (en) 2015-06-01 2021-04-28 メディミューン，エルエルシー Neutralizing anti-influenza binding molecule and its use
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
CN118085055A (en) 2017-04-19 2024-05-28 生物医学研究所 Plasmodium sporozoite NPDP peptides as vaccine and novel malaria vaccine and antibody binding targets
BR112019023776A2 (en) * 2017-05-12 2020-07-28 Memorial Sloan-Kettering Cancer Center method for treating cancer of the central nervous system (snc) in a human subject, antibody or antigen-binding fragment thereof, composition, pharmaceutical composition, method for imaging a tumor in a subject and use of an antibody or fragment of binding to the same antigen
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
CN109550061A (en) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 A kind of kit and application for radioisotope labeling antibody
ES2961791T3 (en) 2018-12-19 2024-03-13 Humabs Biomed Sa Antibodies that neutralize the hepatitis B virus and their uses
MX2022002231A (en) 2019-08-29 2022-03-22 Vir Biotechnology Inc Antibody compositions and methods for treating hepatitis b virus infection.
CN111116701A (en) * 2019-11-14 2020-05-08 浙江普罗亭健康科技有限公司 Intermediate for protein metal marking and preparation method and application thereof
WO2021262840A1 (en) 2020-06-24 2021-12-30 Vir Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
EP4284428A1 (en) 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
US20240166750A1 (en) 2022-10-25 2024-05-23 Ablynx N.V. GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20240209107A1 (en) 2022-12-19 2024-06-27 Sanofi Cd28/ox40 bispecific antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
CA1266344A (en) 1986-02-14 1990-02-27 Miki Kurami High molecular compounds having amino groups, and their utilization
EP0529645B1 (en) * 1986-09-05 1996-10-23 GANSOW, Otto A. Process for the preparation of backbone polysubstituted chelates
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2095141A1 (en) 1990-11-05 1992-05-06 Ingegerd Hellstrom Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
AU661296B2 (en) 1991-01-11 1995-07-20 Cobe Laboratories Inc. Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5403573A (en) 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
KR100307993B1 (en) * 1994-01-24 2001-11-30 고사이 아끼오 Laminates, Laminated Films, and Molded Articles
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6300143B1 (en) 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells

Similar Documents

Publication Publication Date Title
RU2221807C2 (en) Method for radioactive labeling proteins with therapeutic radioactive isotope and set for method realization
RU2001126396A (en) SET FOR RADIOACTIVE LABELING OF PROTEINS ITTREM-90
US5225180A (en) Technetium-99m labeled somatostatin-derived peptides for imaging
US7238340B1 (en) Monoamine, diamide, thiol-containing metal chelating agents
JP2769244B2 (en) Technetium / rhenium labeling method for proteins
US4427646A (en) Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US5219556A (en) Stabilized therapeutic radiopharmaceutical complexes
CA2089881A1 (en) Asialoglycoprotein-conjugated medicinal agent
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
US6261536B1 (en) Post labeling stabilization of radiolabeled proteins and peptides
JPH0399012A (en) Medicine containing n-acetyl-cysteine capable of dosed orally
Lei et al. Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison
US5746996A (en) Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
EP0772459B1 (en) TECHNETIUM-99m LABELED IMAGING AGENTS
IL95723A (en) Method for producing a solution of a technetium-labeled antibody fragment and a kit for radiolabeling an antibody fragment
US5455021A (en) Isotopic tracer composition and method for making and using same
Pak et al. An instant kit method for labeling antimyosin Fab′ with technetium-99m: evaluation in an experimental myocardial infarct model
Mardirossian et al. The stability of 99Tcm directly labelled to an Fab'antibody via stannous ion and mercaptoethanol reduction
US5177192A (en) Method for labeling antibodies with a metal ion
AU709219B2 (en) Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US6395255B1 (en) Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
PT93974A (en) METHOD FOR PREPARING A MIXTURE OF A PEPTIDE OR A PROTEIN AND A HYDROXYPHIDIDONE AND PHARMACEUTICAL COMPOSITIONS
Saha et al. Conditions of radioiodination with iodogen as oxidizing agent
TH60037B (en) A device for the preparation of ethri-90 radioactive substances and proteins.
TH41984A (en) A device for the preparation of ethri-90 radioactive substances and proteins.